Every effort has been made to convert the EPA 2020 scientific programme into a fully virtual programme. Thank you to all the presenters who have submitted their recordings in advance. These are available as on-demand webcasts in the interactive programme. Please note that some presenters were not yet able to pre-record their presentations, therefore there are still some sessions with some missing presentations.
Opioid Epidemiology: Evolutions in Europe - JS009
Co-morbidity: opioid use disorders, pain, depression and suicide. - JS010
Abstract
Abstract Body
Opioid use disorder commonly co-occurs with other psychiatric disorders, especially depression (Torrens et al 2011 ). Also, it is well-documented that depression is common in patients with chronic pain, mainly in patients with severe, multifocal, long-lasting, and disabling pain (Bair et al, 2003). The prescribing of opioid analgesics for pain management-particularly for management of chronic noncancer pain has increased in the last decade (Volkow et al, 2019. Depression is the highest mortality of suicide (30%), followed by substance-use related disorders (18%). Chronic pain deserves special mention because it overlaps with depression to a considerable degree and the fact that the suicide rate is 2–3 times that of control subjects (Bachmann, 2018). In this presentation a review about the comorbidity among opioid use disorders, pain, depression and suicide will be provide.
- Bachmann S. Epidemiology of Suicide and the Psychiatric Perspective. Int J Environ Res Public Health. 2018 Jul 6;15(7).
- Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Arch Intern Med 2003;163:2433-45.
- Torrens M, Gilchrist G, Domingo-Salvany A; psyCoBarcelona Group.Psychiatric comorbidity in illicit drug users: substance-induced versus independent disorders. Drug Alcohol Depend. 2011;113:147-56.
- Volkow N, Benveniste H, McLellan AT. Use and Misuse of Opioids in Chronic Pain 2018; 69:451-465.